Loading…
Celldex Therapeutics, Inc. is projected to rise to $42.17 by 2027, a +33% move from its current price of $31.65. CLDX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $31.04 | $31.65 | $32.27 | -0.01% |
| May 30 | $30.78 | $31.65 | $32.53 | -0.02% |
| May 31 | $30.59 | $31.64 | $32.73 | -0.02% |
| Jun 1 | $30.43 | $31.64 | $32.90 | -0.03% |
| Jun 2 | $30.29 | $31.64 | $33.05 | -0.04% |
| Jun 3 | $30.16 | $31.64 | $33.18 | -0.05% |
| Jun 4 | $30.04 | $31.63 | $33.31 | -0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $30.04 | $31.63 | $33.31 | -0.05% |
| Week 2 | $29.39 | $31.62 | $34.01 | -0.11% |
| Week 3 | $28.90 | $31.60 | $34.55 | -0.16% |
| Week 4 | $28.49 | $31.58 | $35.01 | -0.21% |
| Week 5 | $28.13 | $31.57 | $35.42 | -0.27% |
| Week 6 | $27.80 | $31.55 | $35.80 | -0.32% |
| Week 7 | $27.51 | $31.53 | $36.14 | -0.38% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Celldex Therapeutics, Inc. (CLDX) is a healthcare company focused on developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company develops monoclonal and bispecific antibodies designed to address mast cell mediated diseases where available treatments are inadequate.
Its programs include Barzolvolimab (CDX-0159), a monoclonal antibody that binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases that targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation.
Celldex Therapeutics is headquartered in Hampton, New Jersey.
Celldex Therapeutics, Inc. trades at $30.73 per share, with a market cap of $2.41B, and it is ranked 1882.
The forecast shows a path of growth from 2026 through 2050, with the average price rising from $30.73 in 2026 to $51.27 by 2030, $120.29 by 2040, and $234.65 by 2050.
Forecasted ROIs rise along with the price, from 0% in 2026 to 66.9% by 2030, 291.4% by 2040, and 663.6% by 2050.
Overall, the long-term outlook suggests a bullish trajectory across the forecast horizon.
A major floor 28.7% below — a decisive break under it would weaken the trend.
The nearest floor, 4.7% below — buyers have tended to step in here.
The nearest ceiling, 9.2% above — a clean break opens room to run.
A major ceiling 15.4% above — clearing it would confirm fresh momentum.
Key CLDX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CLDX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $30.94 | Buy | $31.10 | Buy |
| MA 10 | $31.14 | Buy | $31.30 | Buy |
| MA 20 | $32.06 | Sell | $31.76 | Sell |
| MA 50 | $32.13 | Sell | $31.47 | Buy |
| MA 100 | $29.32 | Buy | $30.04 | Buy |
| MA 200 | $27.39 | Buy | $28.21 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.60 | Neutral |
| Stoch RSI (14) | 57.24 | Neutral |
| CCI (20) | -27.22 | Neutral |
| Williams %R (14) | -60.73 | Info |
| MACD (12,26,9) | -0.17 | Sell |
| ROC (12) | -6.83 | Sell |
| Bollinger %B (20,2) | 0.42 | Neutral |
| Stochastic %K (14) | 39.27 | Neutral |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | -1.76 | Sell |
| Ultimate (7,14,28) | 47.17 | Neutral |
| Momentum (10) | -0.35 | Sell |
| Aroon Osc (25) | -36.00 | Sell |
| Hull MA (9) | 30.98 | Buy |
| ADX (14) | 14.03 | Neutral |
| ATR (14) | 0.58 | Info |
The 30-day technical picture shows sentiment NEUTRAL, with RSI14 at 40. The moving averages place the price around key trend lines, with the SMA50 at $32.07 and the SMA200 at $27.28.
Support is identified at $30.15 and resistance at $34.55, framing the near-term trading range. The 30-day price range spans from $26.95 to $35.04, illustrating a broad fluctuation window in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $22.58 | $31.65 | $41.99 | 0% | Neutral | |
| $34.37 | $42.17 | $54.21 | +33% | Bullish | |
| $36.46 | $45.58 | $60.18 | +44% | Bullish | |
| $39.87 | $50.63 | $68.27 | +60% | Bullish | |
| $42.02 | $54.09 | $74.27 | +71% | Bullish | |
| $43.43 | $56.62 | $78.98 | +79% | Bullish | |
| $48.93 | $64.52 | $91.31 | +104% | Bullish | |
| $53.15 | $70.86 | $101.60 | +124% | Bullish | |
| $61.65 | $83.03 | $120.50 | +162% | Bullish | |
| $70.62 | $96.04 | $140.96 | +203% | Bullish | |
| $91.77 | $130.37 | $200.73 | +312% | Bullish | |
| $168.10 | $256.89 | $424.59 | +712% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $22.58 | $31.65 | $37.09 | +0.00% |
| June 2026 | $26.96 | $31.47 | $37.45 | -0.58% |
| July 2026 | $26.77 | $31.43 | $37.77 | -0.12% |
| August 2026 | $27.33 | $32.24 | $39.04 | +2.59% |
| September 2026 | $27.31 | $32.34 | $39.40 | +0.30% |
| October 2026 | $26.86 | $31.92 | $39.10 | -1.31% |
| November 2026 | $27.41 | $32.68 | $40.23 | +2.39% |
| December 2026 | $28.40 | $33.95 | $41.99 | +3.90% |
Click any year to see its month-by-month CLDX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CLDX to range from $22.58 to $41.99 through 2026. The $31.65 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CLDX price prediction for 2027 points to an average of $42.17 (low $34.37, high $54.21) — a potential gain of +33% on today's $31.65. Buyers look set to stay in control over this stretch.
In 2028, CLDX is projected to trade between $36.46 and $60.18, averaging $45.58 — a potential gain of +44% from today's $31.65. That is up +8% on the projected 2027 average. Momentum favours further upside here.
Celldex Therapeutics, Inc.'s 2029 outlook centres on $50.63, within a $39.87 to $68.27 range. That is up +11% on the projected 2028 average. That marks a +60% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CLDX could reach as high as $74.27, with a base case around $54.09 and support toward $42.02 — roughly +71% from $31.65. Momentum favours further upside here.
Expect CLDX to range from $43.43 to $78.98 through 2031. The $56.62 average target implies a +79% move from current prices. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CLDX price prediction for 2032 points to an average of $64.52 (low $48.93, high $91.31) — a potential gain of +104% on today's $31.65. Momentum favours further upside here.
In 2033, CLDX is projected to trade between $53.15 and $101.60, averaging $70.86 — a potential gain of +124% from today's $31.65. That is up +10% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Celldex Therapeutics, Inc.'s 2034 outlook centres on $83.03, within a $61.65 to $120.50 range. That is up +17% on the projected 2033 average. That marks a +162% change versus current levels. Momentum favours further upside here.
By 2035, CLDX could reach as high as $140.96, with a base case around $96.04 and support toward $70.62 — roughly +203% from $31.65. Buyers look set to stay in control over this stretch.
Expect CLDX to range from $91.77 to $200.73 through 2040. The $130.37 average target implies a +312% move from current prices. That is up +36% on the projected 2035 average. Momentum favours further upside here.
The CLDX price prediction for 2050 points to an average of $256.89 (low $168.10, high $424.59) — a potential gain of +712% on today's $31.65. Buyers look set to stay in control over this stretch.
Investing $1,000 in CLDX today (≈ 31.595577 CLDX) could be worth
$8,116.48
+$7,116.48 (+712%) by 2050 · US Dollar
Based on the average projected CLDX price of $256.89 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CLDXwould be worth at today's price.
$1,000 invested in CLDX on May 27, 2025 (≈ 50.556116 CLDX) would be worth
$1,600.1
+$600.1 (+60.0%) today · 1.60× · US Dollar
Based on a CLDX entry price of $19.78 vs. today's $31.65.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $30.9 | $1,024.27 | +2.4% |
| 1 month ago | $33.66 | $940.29 | -6.0% |
| 3 months ago | $30.64 | $1,032.96 | +3.3% |
| 6 months ago | $27.02 | $1,171.35 | +17.1% |
| 1 year ago | $19.78 | $1,600.1 | +60.0% |
| All time (5.0y) ago | $27.78 | $1,139.31 | +13.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CLDX forecast.
Our base-case forecast reaches $63.00 around 2032.
Implied market cap at $63.00: $4.95B
In 2030, the forecast shows min $39.72, avg $51.27, max $70.66, with ROI 66.9% and sentiment BULLISH.
In 2040, the forecast shows min $84.23, avg $120.29, max $186.23, with ROI 291.4% and sentiment BULLISH.
In 2050, the forecast shows min $152.43, avg $234.65, max $390.40, with ROI 663.6% and sentiment BULLISH.
These figures illustrate a strong upward path over the multi-year horizon, though they are estimates and not guarantees. They depend on market conditions and the progression of the company's clinical programs.
Tap a question to reveal the answer.
The 2030 forecast shows min $39.72, avg $51.27, max $70.66; ROI 66.9%; sentiment BULLISH.
Forecasts turn bullish from 2027 onward, with avg prices rising to $40.48 by 2027 and up to $234.65 by 2050, with ROIs reaching 663.6%; these are estimates, not guarantees.
Yes. The forecast shows max prices of $113.54 in 2034 and $131.96 in 2035, indicating a $100 level could be reached within the forecast horizon.
The 30-day range is $26.95 to $35.04; support is $30.15 and resistance is $34.55. RSI is 40, SMA50 is $32.07, SMA200 is $27.28, and annualized volatility is 40%.
Current price is $30.73 and market cap is $2.41B; the stock ranks 1882.
Celldex Therapeutics, Inc. Community Discussion
0Share your Celldex Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.